Intrinsic value of Viveve Medical - VIVE

Previous Close

$2.17

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$2.17

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of VIVE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  24
  38
  57
  82
  116
  159
  213
  280
  361
  456
  566
  692
  834
  992
  1,166
  1,357
  1,563
  1,784
  2,021
  2,272
  2,538
  2,817
  3,111
  3,418
  3,739
  4,073
  4,422
  4,784
  5,161
  5,553
Variable operating expenses, $m
  72
  111
  166
  241
  339
  467
  626
  822
  1,058
  1,336
  1,659
  2,029
  2,445
  2,910
  3,421
  3,980
  4,584
  5,234
  5,928
  6,664
  7,443
  8,263
  9,124
  10,025
  10,966
  11,947
  12,969
  14,033
  15,138
  16,287
Fixed operating expenses, $m
  5
  5
  5
  5
  6
  6
  6
  6
  6
  6
  6
  6
  7
  7
  7
  7
  7
  7
  8
  8
  8
  8
  8
  8
  9
  9
  9
  9
  9
  10
Total operating expenses, $m
  77
  116
  171
  246
  345
  473
  632
  828
  1,064
  1,342
  1,665
  2,035
  2,452
  2,917
  3,428
  3,987
  4,591
  5,241
  5,936
  6,672
  7,451
  8,271
  9,132
  10,033
  10,975
  11,956
  12,978
  14,042
  15,147
  16,297
Operating income, $m
  -52
  -78
  -115
  -164
  -229
  -313
  -419
  -548
  -703
  -887
  -1,100
  -1,344
  -1,618
  -1,924
  -2,262
  -2,630
  -3,028
  -3,457
  -3,914
  -4,400
  -4,913
  -5,454
  -6,022
  -6,615
  -7,236
  -7,883
  -8,557
  -9,257
  -9,986
  -10,744
EBITDA, $m
  -52
  -78
  -114
  -163
  -228
  -311
  -416
  -544
  -699
  -881
  -1,093
  -1,335
  -1,608
  -1,912
  -2,248
  -2,614
  -3,010
  -3,435
  -3,890
  -4,373
  -4,883
  -5,420
  -5,984
  -6,574
  -7,191
  -7,834
  -8,503
  -9,200
  -9,924
  -10,677
Interest expense (income), $m
  1
  5
  4
  8
  12
  18
  27
  37
  50
  67
  86
  109
  136
  167
  201
  240
  283
  329
  379
  433
  491
  552
  617
  685
  756
  831
  909
  991
  1,075
  1,164
  1,256
Earnings before tax, $m
  -57
  -83
  -122
  -176
  -248
  -340
  -456
  -598
  -770
  -973
  -1,209
  -1,480
  -1,785
  -2,126
  -2,502
  -2,912
  -3,357
  -3,836
  -4,347
  -4,891
  -5,465
  -6,071
  -6,706
  -7,372
  -8,067
  -8,792
  -9,547
  -10,333
  -11,150
  -11,999
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -57
  -83
  -122
  -176
  -248
  -340
  -456
  -598
  -770
  -973
  -1,209
  -1,480
  -1,785
  -2,126
  -2,502
  -2,912
  -3,357
  -3,836
  -4,347
  -4,891
  -5,465
  -6,071
  -6,706
  -7,372
  -8,067
  -8,792
  -9,547
  -10,333
  -11,150
  -11,999

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  40
  62
  93
  135
  191
  262
  352
  463
  595
  752
  934
  1,141
  1,376
  1,637
  1,925
  2,239
  2,579
  2,945
  3,335
  3,750
  4,188
  4,649
  5,133
  5,640
  6,170
  6,722
  7,297
  7,895
  8,517
  9,164
Adjusted assets (=assets-cash), $m
  40
  62
  93
  135
  191
  262
  352
  463
  595
  752
  934
  1,141
  1,376
  1,637
  1,925
  2,239
  2,579
  2,945
  3,335
  3,750
  4,188
  4,649
  5,133
  5,640
  6,170
  6,722
  7,297
  7,895
  8,517
  9,164
Revenue / Adjusted assets
  0.600
  0.613
  0.613
  0.607
  0.607
  0.607
  0.605
  0.605
  0.607
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
  0.606
Average production assets, $m
  1
  2
  3
  5
  7
  10
  13
  17
  22
  27
  34
  42
  50
  60
  70
  81
  94
  107
  121
  136
  152
  169
  187
  205
  224
  244
  265
  287
  310
  333
Working capital, $m
  3
  5
  7
  11
  15
  21
  28
  36
  47
  59
  73
  89
  108
  128
  150
  175
  202
  230
  261
  293
  327
  363
  401
  441
  482
  525
  570
  617
  666
  716
Total debt, $m
  27
  46
  74
  112
  162
  226
  307
  407
  526
  667
  831
  1,018
  1,229
  1,464
  1,723
  2,005
  2,312
  2,640
  2,992
  3,365
  3,759
  4,175
  4,610
  5,067
  5,543
  6,040
  6,557
  7,096
  7,656
  8,237
Total liabilities, $m
  36
  56
  84
  122
  172
  236
  317
  416
  536
  677
  840
  1,027
  1,238
  1,473
  1,732
  2,015
  2,321
  2,650
  3,002
  3,375
  3,769
  4,184
  4,620
  5,076
  5,553
  6,050
  6,567
  7,106
  7,665
  8,247
Total equity, $m
  4
  6
  9
  14
  19
  26
  35
  46
  60
  75
  93
  114
  138
  164
  192
  224
  258
  294
  334
  375
  419
  465
  513
  564
  617
  672
  730
  790
  852
  916
Total liabilities and equity, $m
  40
  62
  93
  136
  191
  262
  352
  462
  596
  752
  933
  1,141
  1,376
  1,637
  1,924
  2,239
  2,579
  2,944
  3,336
  3,750
  4,188
  4,649
  5,133
  5,640
  6,170
  6,722
  7,297
  7,896
  8,517
  9,163
Debt-to-equity ratio
  6.590
  7.440
  7.960
  8.280
  8.490
  8.630
  8.720
  8.790
  8.840
  8.870
  8.900
  8.910
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -57
  -83
  -122
  -176
  -248
  -340
  -456
  -598
  -770
  -973
  -1,209
  -1,480
  -1,785
  -2,126
  -2,502
  -2,912
  -3,357
  -3,836
  -4,347
  -4,891
  -5,465
  -6,071
  -6,706
  -7,372
  -8,067
  -8,792
  -9,547
  -10,333
  -11,150
  -11,999
Depreciation, amort., depletion, $m
  0
  0
  1
  1
  1
  2
  3
  3
  4
  5
  7
  8
  10
  12
  14
  16
  19
  21
  24
  27
  30
  34
  37
  41
  45
  49
  53
  57
  62
  67
Funds from operations, $m
  -57
  -82
  -122
  -175
  -246
  -338
  -453
  -595
  -766
  -968
  -1,203
  -1,472
  -1,775
  -2,114
  -2,488
  -2,896
  -3,339
  -3,814
  -4,323
  -4,863
  -5,435
  -6,037
  -6,669
  -7,331
  -8,022
  -8,743
  -9,494
  -10,275
  -11,088
  -11,933
Change in working capital, $m
  1
  2
  2
  3
  4
  6
  7
  9
  10
  12
  14
  16
  18
  20
  23
  25
  27
  29
  31
  32
  34
  36
  38
  40
  41
  43
  45
  47
  49
  51
Cash from operations, $m
  -58
  -84
  -124
  -178
  -251
  -343
  -460
  -604
  -776
  -980
  -1,217
  -1,488
  -1,794
  -2,134
  -2,510
  -2,921
  -3,365
  -3,843
  -4,353
  -4,896
  -5,469
  -6,073
  -6,707
  -7,370
  -8,063
  -8,786
  -9,539
  -10,322
  -11,137
  -11,983
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -2
  -3
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -14
  -16
  -19
  -21
  -24
  -27
  -30
  -34
  -37
  -41
  -45
  -49
  -53
  -57
  -62
New CAPEX, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
Cash from investing activities, $m
  -1
  -1
  -1
  -3
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -15
  -17
  -19
  -22
  -25
  -28
  -32
  -35
  -39
  -43
  -47
  -52
  -55
  -60
  -65
  -70
  -75
  -80
  -86
Free cash flow, $m
  -59
  -85
  -126
  -181
  -254
  -347
  -465
  -610
  -784
  -990
  -1,229
  -1,502
  -1,810
  -2,154
  -2,533
  -2,946
  -3,394
  -3,875
  -4,389
  -4,935
  -5,512
  -6,120
  -6,758
  -7,426
  -8,124
  -8,851
  -9,609
  -10,397
  -11,217
  -12,069
Issuance/(repayment) of debt, $m
  -2
  20
  28
  38
  50
  64
  81
  99
  119
  141
  164
  187
  211
  235
  259
  283
  306
  329
  351
  373
  394
  415
  436
  456
  477
  497
  517
  538
  560
  582
Issuance/(repurchase) of shares, $m
  75
  85
  125
  180
  253
  347
  465
  609
  783
  989
  1,228
  1,501
  1,809
  2,152
  2,530
  2,944
  3,391
  3,872
  4,386
  4,932
  5,509
  6,117
  6,755
  7,422
  8,120
  8,847
  9,605
  10,393
  11,212
  12,064
Cash from financing (excl. dividends), $m  
  73
  105
  153
  218
  303
  411
  546
  708
  902
  1,130
  1,392
  1,688
  2,020
  2,387
  2,789
  3,227
  3,697
  4,201
  4,737
  5,305
  5,903
  6,532
  7,191
  7,878
  8,597
  9,344
  10,122
  10,931
  11,772
  12,646
Total cash flow (excl. dividends), $m
  14
  20
  28
  38
  50
  64
  80
  98
  118
  140
  162
  186
  209
  233
  257
  281
  304
  326
  348
  370
  391
  412
  432
  453
  473
  493
  513
  534
  555
  577
Retained Cash Flow (-), $m
  -75
  -85
  -125
  -180
  -253
  -347
  -465
  -609
  -783
  -989
  -1,228
  -1,501
  -1,809
  -2,152
  -2,530
  -2,944
  -3,391
  -3,872
  -4,386
  -4,932
  -5,509
  -6,117
  -6,755
  -7,422
  -8,120
  -8,847
  -9,605
  -10,393
  -11,212
  -12,064
Prev. year cash balance distribution, $m
  11
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -50
  -65
  -98
  -143
  -204
  -283
  -384
  -511
  -665
  -849
  -1,065
  -1,315
  -1,599
  -1,919
  -2,274
  -2,663
  -3,088
  -3,546
  -4,038
  -4,562
  -5,118
  -5,705
  -6,322
  -6,970
  -7,647
  -8,354
  -9,091
  -9,859
  -10,657
  -11,487
Discount rate, %
  7.80
  8.19
  8.60
  9.03
  9.48
  9.95
  10.45
  10.98
  11.52
  12.10
  12.71
  13.34
  14.01
  14.71
  15.44
  16.22
  17.03
  17.88
  18.77
  19.71
  20.70
  21.73
  22.82
  23.96
  25.16
  26.41
  27.73
  29.12
  30.58
  32.11
PV of cash for distribution, $m
  -46
  -56
  -76
  -101
  -129
  -160
  -192
  -222
  -249
  -271
  -286
  -293
  -291
  -281
  -264
  -241
  -213
  -184
  -154
  -125
  -99
  -75
  -56
  -40
  -28
  -19
  -12
  -8
  -5
  -3
Current shareholders' claim on cash, %
  50.0
  2.3
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

FINANCIAL RATIOS  of  Viveve Medical (VIVE)

Valuation Ratios
P/E Ratio -1.2
Price to Sales 3.3
Price to Book 0
Price to Tangible Book
Price to Cash Flow -1.3
Price to Free Cash Flow -1.3
Growth Rates
Sales Growth Rate 600%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage -19
Management Effectiveness
Return On Assets -146.2%
Ret/ On Assets - 3 Yr. Avg. -243.6%
Return On Total Capital -222.2%
Ret/ On T. Cap. - 3 Yr. Avg. -554.1%
Return On Equity -1000%
Return On Equity - 3 Yr. Avg. -550%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 42.9%
Gross Margin - 3 Yr. Avg. 14.3%
EBITDA Margin -271.4%
EBITDA Margin - 3 Yr. Avg. -490.5%
Operating Margin -271.4%
Oper. Margin - 3 Yr. Avg. -490.5%
Pre-Tax Margin -285.7%
Pre-Tax Margin - 3 Yr. Avg. -495.2%
Net Profit Margin -285.7%
Net Profit Margin - 3 Yr. Avg. -495.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

VIVE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the VIVE stock intrinsic value calculation we used $15.288 million for the last fiscal year's total revenue generated by Viveve Medical. The default revenue input number comes from 0001 income statement of Viveve Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our VIVE stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.8%, whose default value for VIVE is calculated based on our internal credit rating of Viveve Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Viveve Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of VIVE stock the variable cost ratio is equal to 293.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $5 million in the base year in the intrinsic value calculation for VIVE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 16.4% for Viveve Medical.

Corporate tax rate of 27% is the nominal tax rate for Viveve Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the VIVE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for VIVE are equal to 6%.

Life of production assets of 2 years is the average useful life of capital assets used in Viveve Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for VIVE is equal to 12.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-2.6 million for Viveve Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 31.489 million for Viveve Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Viveve Medical at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
UTMD Utah Medical P 86.90 59.28  sell
HOLX Hologic 40.97 27.04  sell
COO Cooper 261.75 429.58  str.buy
JNJ Johnson&Johnso 145.62 176.79  buy
CUTR Cutera 20.10 38.15  hold

COMPANY NEWS

▶ Viveve to Present at Stifel 2018 Healthcare Conference   [Nov-08-18 05:30PM  GlobeNewswire]
▶ Viveve Appoints Two New Independent Board Members   [Sep-13-18 08:28AM  GlobeNewswire]
▶ VIVE: FDA Warning Letter Should Weed-Out Imposters and Benefit VIVE   [Aug-02-18 12:15PM  Zacks Small Cap Research]
▶ What Is Viveve Medical Incs (NASDAQ:VIVE) Share Price Doing?   [Jun-26-18 11:55AM  Simply Wall St.]
▶ Viveve to Present at Jefferies Global Healthcare Conference   [May-29-18 08:24AM  GlobeNewswire]
▶ Viveve Announces Initiation of VIVEVE II Clinical Study   [May-16-18 08:24AM  GlobeNewswire]
▶ Viveve Reports First Quarter 2018 Financial Results   [May-10-18 04:07PM  GlobeNewswire]
▶ Viveve to Announce First Quarter 2018 Financial Results   [May-03-18 08:28AM  GlobeNewswire]
▶ Viveve to Present at March Investor Conferences   [Feb-27-18 08:28AM  Marketwired]
▶ Viveve to Participate in BTIG Healthcare Conference   [Feb-22-18 08:28AM  Marketwired]
▶ Viveve Announces Third Quarter 2017 Financial Results   [Nov-08-17 04:02PM  Marketwired]
▶ Viveve to Present at November Investor Conferences   [Nov-02-17 08:28AM  Marketwired]
▶ VIVE: Q3 Revenue Beats, Details Imply Strong Q4   [Oct-23-17 08:00AM  Zacks Small Cap Research]
▶ VIVE: Anticipating IDE Approval, Utilization Jumps   [Aug-22-17 10:00AM  Zacks Small Cap Research]
▶ Viveve Secures $30 million Debt Financing with CRG   [May-23-17 04:02PM  Marketwired]
▶ VIVE: U.S. Demand Robust, Driving Revenue and Margins   [May-22-17 11:30AM  Zacks Small Cap Research]
▶ Viveve Reports First Quarter 2017 Financial Results   [May-11-17 04:02PM  Marketwired]
▶ Viveve Product Review Financial Analysis and Guidance   [Apr-20-17 08:00AM  Accesswire]
▶ VIVE: Guiding for ~100%+ Revenue Growth in 2017   [Feb-21-17 02:00PM  Zacks Small Cap Research]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.